Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug;26(7-8):401-408.
doi: 10.1007/s12471-018-1122-4.

Transcatheter aortic valve replacement with the 34 mm Medtronic Evolut valve : Early results of single institution experience

G D'Ancona  1   2 , M Dißmann  3 , H Heinze  4 , D Zohlnhöfer-Momm  5 , H Ince  6   7 , S Kische  6   7
Affiliations

Transcatheter aortic valve replacement with the 34 mm Medtronic Evolut valve : Early results of single institution experience

G D'Ancona et al. Neth Heart J. 2018 Aug.

Abstract

Objectives: To report our experience with the recently introduced 34 mm Evolut transcatheter aortic valve replacement (TAVR) prosthesis.

Background: A larger TAVR prosthesis has become available for the treatment of aortic stenosis (AVS) in larger native aortic annuli (up to 30 mm). Outcomes with this new device are still unreported.

Results: The first 25 transfemoral TAVRs performed by our team with the self-expandable 34 mm Evolut are presented. The majority of patients were male (84%) with a mean age of 81.3 ± 5.6 years, a median logistic euro-SCORE of 14.7 (5.4-61.0), and a computed tomography measured mean perimeter-derived aortic annulus diameter of 27.1 ± 1.4 mm (min. 25.0-max. 31.2 mm). We implanted one 34 mm Evolut in all patients. Median operative time and radiation time were 68.5 and 12.4 min respectively. To optimise final valve position and haemodynamic performance, at least one complete re-sheathing and re-positioning of the same valve was reported in 33.2%. New permanent pacemaker implantation (PPMI) was necessary in 28.5%. At Receiver Operating Characteristic (ROC) analysis, a minimal diameter of the left ventricular outflow tract <21.9 mm was a significant predictor for PPMI (specificity 82%; sensitivity 83%; p = 0.005; Area Under the Curve (AUC) = 0.9). Length of stay in hospital was 9.2 ± 5.8 days and no in-hospital death was reported. At discharge, grade 1 + para-valvular regurgitation was present in 32%, and no regurgitation in the remaining patients. Device success and early safety were 100% and 92% respectively.

Conclusions: TAVR with the 34 mm Evolut prosthesis has shown satisfactory acute outcomes. Although results are consistent with those observed with smaller Evolut prostheses, a trend for a higher PPMI rate has been noticed and could derive from a higher oversizing rate.

Keywords: Aorta; Large; Prosthesis; Transcatheter; Valve.

PubMed Disclaimer

Conflict of interest statement

G. D’Ancona, M. Dißmann, H. Heinze, D. Zohlnhöfer-Momm, H. Ince and S. Kische declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
CoreValve Evolut R size selection according to range of native aortic annulus diameters/perimeters (courtesy of Medtronic, Inc., Minneapolis, Minnesota)
See this image and copyright information in PMC

References

    1. Manoharan G, Walton AS, Brecker SJ, et al. Treatment of symptomatic severe aortic stenosis with a novel resheathable supra-annular self-expanding transcatheter aortic valve system. Jacc Cardiovasc Interv. 2015;8:1359–1367. doi: 10.1016/j.jcin.2015.05.015. - DOI - PubMed
    1. Popma JJ, Reardon MJ, Khabbaz K, et al. Early clinical outcomes after transcatheter aortic valve replacement using a novel self-expanding bioprosthesis in patients with severe aortic stenosis who are suboptimal for surgery: results of the Evolut R U.S. Study. Jacc Cardiovasc Interv. 2017;10:268–275. doi: 10.1016/j.jcin.2016.08.050. - DOI - PubMed
    1. Kappetein AP, Head SJ, Généreux P, et al. Valve Academic Research Consortium-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013;145:6–23. doi: 10.1016/j.jtcvs.2012.09.002. - DOI - PubMed
    1. Petronio AS, Sinning JM, Van Mieghem N, et al. Optimal implantation depth and adherence to guidelines on permanent pacing to improve the results of transcatheter aortic valve replacement with the Medtronic Core Valve system. JACC Cardiovasc. Interv. 2015;8:837–846. doi: 10.1016/j.jcin.2015.02.005. - DOI - PubMed
    1. Dowling C, Firoozi S, Doyle N, et al. Initial experience of the medtronic 34 mm evolut R Valve: The UK & Ireland Implanters’ Registry. J Am Coll Cardiol. 2017;70:B263. doi: 10.1016/j.jacc.2017.09.659. - DOI

LinkOut - more resources